Regenerex Pharma (RGPX) Long-Term Debt Repayments (2022 - 2025)
Regenerex Pharma (RGPX) reported Long-Term Debt Repayments of $87498.0 for Q3 2025, up 395.68% on a QoQ basis from $17652.0 in Q2 2025.
Regenerex Pharma (RGPX) has 4 years of Long-Term Debt Repayments data on file, last reported at $87498.0 in Q3 2025.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $87498.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $158510.0 (changed N/A YoY) and the FY2025 annual result came in at $284460.0, up 137.05% from the prior year.
- Long-Term Debt Repayments advanced to $87498.0 in Q3 2025 per RGPX's latest filing, from $17652.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $87498.0 in Q3 2025 and bottomed at $2500.0 in Q4 2022.
- The 4-year median for Long-Term Debt Repayments is $35357.0 (2023), against an average of $40338.1.
- The widest annual swing landed in 2024, when Long-Term Debt Repayments surged 127.68%; it then plunged 66.92% in 2025.
- Tracing RGPX's Long-Term Debt Repayments over 4 years: stood at $2500.0 in 2022, then jumped by 120.0% to $5500.0 in 2023, then surged by 870.18% to $53360.0 in 2024, then surged by 63.98% to $87498.0 in 2025.
- Per Business Quant, the three latest RGPX Long-Term Debt Repayments figures stand at $87498.0 (Q3 2025), $17652.0 (Q2 2025), and $53360.0 (Q2 2024).
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 87,498.00 |
| Sep 30, 2025 | 87,498.00 |
| Jun 30, 2025 | 17,652.00 |
| Jun 30, 2025 | 17,652.00 |
| Jun 30, 2024 | 53,360.00 |
| Jun 30, 2024 | 53,360.00 |
| Mar 31, 2024 | 80,500.00 |
| Mar 31, 2024 | 80,500.00 |
| Dec 31, 2023 | 5,500.00 |
| Dec 31, 2023 | 5,500.00 |
| Mar 31, 2023 | 35,357.00 |
| Mar 31, 2023 | 35,357.00 |
| Dec 31, 2022 | 2,500.00 |
| Dec 31, 2022 | 2,500.00 |